Tag Archives: AMZN

SpaceX, Elon Musk’s Rocket and Satellite Company, Reportedly Leans Toward Nasdaq Listing, Aiming for “Quick Inclusion” in Nasdaq-100

According to four sources familiar with the matter, SpaceX, the rocket and satellite company owned by Elon Musk, is inclined to list on the Nasdaq, which could become the largest IPO in history. Two of the sources indicated that SpaceX wants to be quickly included in the Nasdaq-100 Index (Nasdaq:NDX) and considers this a necessary condition for listing on the tech-heavy exchange. They also emphasized that SpaceX’s listing plans are still subject to changes.

Other sources mentioned that the New York Stock Exchange (NYSE) is also vying for the listing, but as of now, neither exchange has received a final decision from SpaceX. It was previously reported that SpaceX might launch its IPO as early as June this year.

The Nasdaq-100 Index, compiled by Nasdaq (Nasdaq:NDAQ), is regarded by large institutional investors as a benchmark for top blue-chip stocks and is a global indicator of performance for many of the world’s largest public companies, including tech giants such as (NASDAQ:NVDA), (NASDAQ:AAPL), and (NASDAQ:AMZN). The index rose about 21% last year and has seen a slight pullback so far this year.

Last month, the Nasdaq introduced a new rule that could shorten the time for large-cap companies newly listed on the exchange to be included in the Nasdaq-100 Index.

This amendment is aimed at attracting high-valued private companies like SpaceX, Anthropic, and OpenAI to list on Nasdaq. The rule has yet to be finalized and may take several months before it comes into effect.

Under the proposed “quick inclusion” rule, if a newly listed company’s market capitalization ranks within the top 40 of the Nasdaq-100’s current constituent stocks, it could be added to the index within less than a month. One source revealed that SpaceX’s IPO valuation target is about $1.75 trillion, and based on the current stock price, the company would become the sixth-largest U.S. company by market value after its listing.

Currently, newly listed companies typically have to wait up to a year before meeting the inclusion criteria for major indexes like the S&P 500 or Nasdaq-100. They must first prove their stability to attract substantial institutional investor buying.

Advantages of Index Inclusion

Being added to blue-chip indexes such as the Nasdaq-100 or S&P 500 makes it easier for companies to attract funding from large institutional investors. These institutions typically build large positions in index funds, which helps broaden the shareholder base and gradually increase stock liquidity.

While the NYSE also tracks similar indexes for the largest 100 U.S. stocks, the market’s focus is lower compared to Nasdaq, making inclusion in the Nasdaq-100 particularly important for large-cap IPOs.

For company management and early investors, stronger liquidity helps reduce the impact of large sell-offs on the stock price after the IPO lock-up period (usually 90 to 180 days). However, this does not entirely avoid the pressure on stock prices caused by large-scale insider selling.

As of the time of writing, SpaceX has not commented on the matter.

In February, it was reported that SpaceX’s advisory team had been in talks with major index providers such as Nasdaq regarding the possibility of early inclusion in core indexes.

SpaceX’s potential IPO is expected to be one of the most anticipated offerings in recent years. Currently, several well-known venture-backed companies and startups, including OpenAI and Anthropic, are also preparing for their public listings.

OpenAI Races Towards $100 Billion Financing, Altman Claims ChatGPT’s Monthly Growth Rate Returns to Over 10%

Amid growing competitive pressure, OpenAI CEO Sam Altman has informed both employees and investors that the company is maintaining strong momentum in its development.

According to an internal Slack message seen by the media, Altman told OpenAI employees last Friday that the company’s popular AI chatbot, ChatGPT, has “reached a monthly growth rate of over 10% once again.” He also mentioned that OpenAI is preparing to launch an “upgraded chatbot model” this week.

Currently, ChatGPT has surpassed 800 million weekly users, but Google(GOOGL) and Anthropic are steadily eating into its market share. In December last year, OpenAI announced that it had entered a “Code Red” state to make comprehensive improvements to ChatGPT, temporarily putting several projects on hold and concentrating resources on this goal.

In Friday’s internal communication, Altman also mentioned that OpenAI’s programming product Codex had seen a growth of about 50% over the past week.

Codex competes directly with Anthropic’s Claude Code, which has gained a large number of users over the past year.

Last week, OpenAI released a new Codex model—GPT-5.3-Codex—and launched a standalone app for users with Apple computers. According to internal messages, Altman described the growth of Codex as “absolutely crazy.”

“It’s been an amazing week,” Altman wrote.

Investor Messaging
Insiders revealed that as OpenAI approaches completing a financing round that could reach up to $100 billion, Altman and CFO Sarah Friar have been actively pitching the company’s growth story to investors.

In private discussions, the two executives emphasized OpenAI’s advantages in the consumer sector, the expanding enterprise business, and its access to computing resources.

As part of the fundraising discussions, OpenAI presented investors with several charts. According to internal data, Codex is steadily capturing market share from Claude Code.

Insiders said that OpenAI expects the fundraising negotiations to intensify over the next two weeks.

As previously reported, OpenAI’s financing round may occur in two phases. The first phase could involve funding from Microsoft(MSFT), NVIDIA(NVDA), and Amazon(AMZN), with Amazon discussing a potential $50 billion investment in OpenAI. Following this, additional investments from entities like SoftBank could come into play, with SoftBank reportedly considering a $30 billion investment.

However, the specific details of this financing round are still in flux, and the final structure may change.

Ad Testing Launched
On Monday, OpenAI announced the launch of an ad test for ChatGPT in the United States, available to certain free and Go plan subscribers.

OpenAI stated that these ads will be clearly labeled and will appear at the bottom of the chatbot’s responses without affecting the content of the answers.

The digital advertising market has long been dominated by Google and Meta, with Amazon gradually becoming an important player in recent years.

It is reported that OpenAI expects that, in the long term, ad revenue will account for less than half of its overall earnings.

AI Arms Race Sparks Semiconductor Surge, NVIDIA Rises Nearly 8%, Achieving the Strongest Rally in 10 Months

The AI “arms race” has triggered a semiconductor frenzy, with NVIDIA (NASDAQ:NVDA) stock surging nearly 8%, marking its strongest rise in nearly 10 months. Earlier, six of the seven tech giants had already reported their earnings, with the most noteworthy being that Google (NASDAQ:GOOGL), Microsoft (NASDAQ:MSFT), Amazon (NASDAQ:AMZN), and Meta Platforms (NASDAQ:META) will collectively spend approximately $650 billion on capital expenditures in 2026.

Last week, Meta announced its capital expenditures would rise to as much as $135 billion for the year, representing an 87% increase. Meanwhile, Microsoft reported a 66% year-on-year growth in its capital expenditures for Q2, and analysts predict its fiscal year capital spending through June will approach $105 billion.

Jensen Huang, CEO of NVIDIA, specifically praised OpenAI and Anthropic, two leading AI labs, stating that both are “making a lot of money.” NVIDIA invested $10 billion in Anthropic last year, and Huang earlier this week indicated plans to significantly invest in OpenAI’s next funding round. He mentioned, “If they can have twice the computing power, their revenue will increase fourfold.”

Earlier, Taiwan Semiconductor Manufacturing Company (NYSE:TSM), the world’s leading semiconductor foundry, set new performance records and announced plans to significantly increase its capital expenditures to $52-56 billion in 2026, far exceeding market expectations. This is aimed at accelerating the expansion of advanced manufacturing capacity to address the ongoing global shortage of AI chips.

CPO Industry Accelerates, Lumentum Surges Over 9%

NVIDIA, in a recent webinar, announced that three partners—CoreWeave (NYSE:CRWV), Lambda, and TACC—will deploy the IB CPO system in the first half of 2026, and Ethernet CPO products are expected to start shipping in the second half of 2026. The company believes that the CPO industry is advancing more quickly than expected, with the technology first landing in scale-out scenarios and expanding into larger market spaces. As a next-generation optical interconnect solution, the commercial value of CPO continues to become clearer, and its market potential is expanding.

Lumentum (NASDAQ:LITE) CEO Michael Hurlston stated in a recent earnings call that the company’s ongoing growth is primarily driven by cloud optical modules, OCS, and CPO. The development of the OCS business has exceeded expectations, with the first $10 million quarterly revenue target, initially set for Q3, being reached ahead of schedule. Demand for OCS from three core customers has surged, and Hurlston revealed that there is a backlog of over $400 million in OCS orders, most of which are planned to be delivered in the second half of 2026. Orders and revenue are expected to continue growing as they enter 2027.

Roivant Sciences Surges Over 22% After Promising Skin Disease Results

Roivant Sciences (NASDAQ:ROIV) saw its stock rise more than 22% after its subsidiary Priovant Therapeutics reported positive results from the phase 2 trial of its experimental drug brepocitinib. The drug showed improvements in the activity of skin nodular disease at higher doses. Another subsidiary, Pulmovant, also announced the completion of phase 2 trial enrollment involving around 120 patients for its experimental drug mosliciguat, aimed at treating pulmonary arterial hypertension associated with lung disease.

Priovant reported that patients taking a 45 mg dose showed a 22.3-point improvement on a key skin scoring system at week 16, while the placebo group showed only a 0.7-point improvement. The company noted that all patients in the 45 mg group showed significant improvement, with 62% achieving near-complete skin clearance, and 69% achieving complete or nearly complete clearance, while none of the placebo group patients achieved similar results.

Priovant plans to launch phase 3 trials in 2026, following consultations with the U.S. Food and Drug Administration (FDA).